JP2008501802A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501802A5
JP2008501802A5 JP2007527639A JP2007527639A JP2008501802A5 JP 2008501802 A5 JP2008501802 A5 JP 2008501802A5 JP 2007527639 A JP2007527639 A JP 2007527639A JP 2007527639 A JP2007527639 A JP 2007527639A JP 2008501802 A5 JP2008501802 A5 JP 2008501802A5
Authority
JP
Japan
Prior art keywords
solid dispersion
pharmaceutical composition
polymer
amorphous
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007527639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019929 external-priority patent/WO2005123076A2/en
Publication of JP2008501802A publication Critical patent/JP2008501802A/ja
Publication of JP2008501802A5 publication Critical patent/JP2008501802A5/ja
Pending legal-status Critical Current

Links

Images

JP2007527639A 2004-06-08 2005-06-08 医薬組成物 Pending JP2008501802A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57804304P 2004-06-08 2004-06-08
PCT/US2005/019929 WO2005123076A2 (en) 2004-06-08 2005-06-08 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012000814A Division JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Publications (2)

Publication Number Publication Date
JP2008501802A JP2008501802A (ja) 2008-01-24
JP2008501802A5 true JP2008501802A5 (OSRAM) 2008-07-24

Family

ID=35510250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527639A Pending JP2008501802A (ja) 2004-06-08 2005-06-08 医薬組成物
JP2012000814A Expired - Fee Related JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012000814A Expired - Fee Related JP5337262B2 (ja) 2004-06-08 2012-01-05 医薬組成物

Country Status (18)

Country Link
US (2) US20060089385A1 (OSRAM)
EP (1) EP1765283A4 (OSRAM)
JP (2) JP2008501802A (OSRAM)
KR (2) KR20120039763A (OSRAM)
CN (2) CN1988885A (OSRAM)
AR (1) AR049297A1 (OSRAM)
AU (1) AU2005253957B2 (OSRAM)
BR (1) BRPI0511900A (OSRAM)
CA (1) CA2569310A1 (OSRAM)
IL (2) IL179809A (OSRAM)
MX (1) MXPA06014253A (OSRAM)
NO (1) NO20070130L (OSRAM)
NZ (1) NZ588471A (OSRAM)
RU (1) RU2373923C2 (OSRAM)
SG (1) SG153800A1 (OSRAM)
TW (1) TWI389688B (OSRAM)
WO (1) WO2005123076A2 (OSRAM)
ZA (2) ZA200700030B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1133649C (zh) * 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
ES2572980T3 (es) * 2005-06-02 2016-06-03 Merck Sharp & Dohme Corp. Combinación de inhibidores de la proteasa del VHC con un tensioactivo
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8039475B2 (en) * 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP5646814B2 (ja) * 2006-03-06 2014-12-24 アッヴィ・インコーポレイテッド Ｈｃｖを治療するためのリトナビルの組成物及び使用方法
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
NZ571934A (en) * 2006-03-20 2012-05-25 Vertex Pharma Methods of spray drying formulations of vx-950 (telaprevir)
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
WO2008074035A1 (en) * 2006-12-27 2008-06-19 Abbott Laboratories Hcv protease inhibitors and uses thereof
KR20090118982A (ko) * 2007-02-23 2009-11-18 아베라 파마슈티칼스, 인크. 약학 제제
EP2134717A2 (en) * 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
PT2114924E (pt) * 2007-02-27 2012-04-03 Vertex Pharma Co-cristais e composições farmacêuticas que compreendem os mesmos
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ES2391625T3 (es) * 2007-06-07 2012-11-28 Novartis Ag Formas amorfas estabilizadas de mestilato de imatinib
JP5443360B2 (ja) * 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
JP5095824B2 (ja) 2007-10-10 2012-12-12 ノバルティス アーゲー スピロピロリジン類およびｈｃｖおよびｈｉｖ感染に対するその使用
MX2010004292A (es) * 2007-10-19 2010-08-02 Abbott Gmbh & Co Kg Producto de dispersion solida que contiene un compuesto a base de n-aril urea.
JP2011503060A (ja) * 2007-11-05 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０、ｐｅｇ−ｉｆｎおよびリババリンを含むｈｃｖ併用治療剤
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CA2738477A1 (en) 2008-09-24 2010-04-01 Robert S. Kauffman Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EP2539334A1 (en) * 2010-02-25 2013-01-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Process for the preparation of -acyloxy -formamido amides
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
CN103491964A (zh) * 2011-03-08 2014-01-01 扎里卡斯药品有限公司 固体分散体制剂及其使用方法
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US20130172239A1 (en) * 2011-12-29 2013-07-04 Abbvie Inc. Solid compositions
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
ITMI20120608A1 (it) * 2012-04-13 2013-10-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
WO2013178031A1 (en) * 2012-06-01 2013-12-05 Sunshine Lake Pharma Co., Ltd. New forms of telaprevir and preparation methods thereof
WO2014096343A1 (en) * 2012-12-21 2014-06-26 Sandoz Ag Novel forms of telaprevir
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
JP6130585B2 (ja) 2013-03-15 2017-05-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 無定形状態のｈｃｖ阻害薬の固体経口投薬製剤
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110193013B (zh) * 2019-07-02 2022-02-08 力品药业(厦门)股份有限公司 一种去乙酰真菌环氧乙酯固体分散体及其制备方法
IL316812A (en) * 2022-05-16 2025-01-01 Day One Biopharmaceuticals Inc PAN-RAF kinase inhibitor oral liquid suspension
TW202428307A (zh) * 2022-10-12 2024-07-16 日商中外製藥股份有限公司 包含胜肽、界面活性劑及聚合物的組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US6627760B1 (en) * 2001-06-25 2003-09-30 Astrazeneca Ab Amorphous compound
KR20050044450A (ko) * 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms

Similar Documents

Publication Publication Date Title
JP2008501802A5 (OSRAM)
RU2006147247A (ru) Фармацевтические композиции
JP2009530415A5 (OSRAM)
JP2009530415A (ja) 医薬組成物
TWI666020B (zh) 固體分散製劑
JP2018503595A (ja) ペプチド模倣大環状分子およびその製剤
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
CN103118681A (zh) 固体组合物
AU2013358897A1 (en) Pharmaceutical compositions
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
CN103228278A (zh) 治疗hcv感染的组合疗法
WO2011063076A1 (en) Methods of treating hepatitis c virus with oxoacetamide compounds
CN101068829B (zh) 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
CN110958880A (zh) 固体分散制剂
WO2006132342A1 (ja) ロフルミラスト点眼液
US10308937B2 (en) Combination long acting compositions and methods for Hepatitis C
KR20170083108A (ko) C형 간염에 대한 장기 작용 약학적 조성물
CN104780921A (zh) Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合
JPWO2001087303A1 (ja) 水性液剤
DE602004010291T2 (de) Hcv-hemmende sulfonamide
JP2016538312A (ja) 非晶質のコビシスタットの固体分散体
JPS60166613A (ja) 肝疾患治療剤
KR20140003203A (ko) 설폰아미드계 화합물을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물